This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
The Bruton’s tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Medscape Medical News